EntreMed (ENMD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom R. Clarksburg who wrote (510)	5/4/1998 12:56:00 PM
From: David Winkler	Read Replies (2) of 2135

This was cut from post 344 this site: ENMD receives orphan drug designation... ROCKVILLE, Md.--(BW HealthWire)--March 3, 1998--EntreMed Inc. (Nasdaq: ENMD) today announced that it has received orphan drug designation from The Food and Drug Administration (FDA) for thalidomide as a treatment for primary brain malignancies. If the FDA ultimately approves the use of thalidomide for this indication, orphan drug designation will entitle EntreMed to exclusive marketing rights for the use of thalidomide in the treatment of primary brain malignancies for a seven-year period.... Comments? This says it all!!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next